PureTech Health plc (LON:PRTC)

Market Cap	282.34M
Revenue (ttm)	4.66M
Net Income (ttm)	36.99M
Shares Out	241.32M
EPS (ttm)	0.15
PE Ratio	7.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	533,478
Average Volume	690,704
Open	120.00
Previous Close	116.40
Day's Range	115.80 - 120.00
52-Week Range	100.40 - 178.00
Beta	0.82
RSI	30.67
Earnings Date	Aug 22, 2025

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 56
• Stock Exchange: London Stock Exchange
• Ticker Symbol: PRTC

Financial Performance

Financial numbers in USD